Clinical trials: Cushing's Syndrome
Adrenal Incidentalomas, Cushing Syndrome
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome
- Trial name
- NCT06801249
- Testing
- Metarapone, Standardized antihypertensive therapy
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Osteoporosis, Cortisol Excess
Prevalence of Hidden Hypercortisolism in Osteoporosis
The goals of this observational study are the following: i) to assess the prevalence of hidden hypercortisolism (HidHyCo) in a sample of osteoporotic patients; ii) to compare the clinical characteristics between…
- Trial name
- OSTCOR (NCT05762549)
- Where
- 5 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Auxologico Italiano
Cushing's Syndrome, Postoperative
Contralateral Adrenal Volume Predicts Duration of Postoperative Steroid Replacement Therapy in Non-ACTH-dependent Hypercortisolism
To identify preoperative factors influencing the duration of steroid replacement therapy after adrenalectomy/adrenal-sparing surgery in patients with non-ACTH-dependent hypercortisolism.
- Conditions
- Cushing's Syndrome, Postoperative, Glucocorticoid, Prediction
- Trial name
- NCT07282223
- Testing
- observational diagnostic model development
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Peking University First Hospital
Cushing s Syndrome
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
In previous clinical practice, 68Ga-Pentixafor PET/CT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms.
- Trial name
- NCT07350707
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking Union Medical College Hospital
Adrenal Tumour With Mild Hypercortisolism
Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome
Incidental findings of adrenal tumours,"incidentalomas", occur in 1-5 % in the general population and 10-25 % of these patients will exhibit biochemical mild hypercortisolism.
- Trial name
- AUSC (NCT01246739)
- Testing
- Adrenalectomy
- Where
- 4 sites in Denmark, Norway and 1 more
- Volunteers
- 34 people
- Sponsor
- Region Skane
Cushing's Syndrome
Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome
Patients with Cushing disease have hormone producing tumors in their pituitary gland. Often these tumors are so small they cannot be detected by magnetic resonance imaging (MRI).
- Trial name
- NCT00001453
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing Syndrome
Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors
Patients with tumors in both adrenal glands and slightly elevated cortisol (subclinical Cushings syndrome) are offered to go through an adrenal venous sampling to try to quantify if the overproduction of cortisol is from one…
- Trial name
- AVS (NCT02543697)
- Testing
- Adrenal venous sampling
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- Haukeland University Hospital
Diabetes, Obesity & Overweight
Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or…
- Conditions
- Diabetes, Obesity & Overweight, Cushing Syndrome, Metabolic Diseases
- Trial name
- SARC-ENDO (NCT07703683)
- Testing
- GLP-1 Receptor Agonists
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia
First-in-human Evaluation of [18F]CETO
Purpose of this clinical phase 1 trial was to determine if para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia, Adrenal Cushing Syndrome, Non-Secretory Adrenal Adenoma
- Trial name
- NCT05361083
- Testing
- F18CETO
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Cushing's Disease, Hypercortisolism
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress.
- Conditions
- Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
- Trial name
- OPTIMAL (NCT06701838)
- Testing
- 11C-Methionine PET/CT
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Cushing Syndrome
Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma
Objective: To determine the metabolic effects of the adrenalectomy in subclinical Cushing's syndrome of adrenal incidentaloma. Methods: 234 subclinical cushing syndrome and adrenal incidentaloma will be randomly assigned into two…
- Trial name
- NCT01382420
- Testing
- surgery
- Where
- South Korea
- Volunteers
- 234 people
- Sponsor
- Samsung Medical Center
Mild Autonomous Cortisol Excess
An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
The purpose of this research study is to determine if treatment with Elagolix will improve body weight, waist circumference, muscle strength, cortisol secretion, blood glucose, cholesterol, and bone quality as well as mood and…
- Trial name
- NCT05038878
- Testing
- Elagolix
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cushing's Syndrome
Study of Depression, Peptides, and Steroids in Cushing's Syndrome
OBJECTIVES: I. Study the relationship between dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and disorders of mood, vegetative function, and cognition in patients with Cushing's disease. II.
- Trial name
- NCT00004334
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Center for Research Resources (NCRR)
Cushing's Syndrome
Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome
OBJECTIVES: I. Evaluate whether chronic hypercortisolemia is specifically toxic to hippocampal cells and causes structural reduction of hippocampal volume in patients with Cushing's syndrome. II.
- Trial name
- NCT00004326
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Center for Research Resources (NCRR)
Cushing's Syndrome, Pituitary Adenoma
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands.
- Conditions
- Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease
- Trial name
- NCT00001452
- Testing
- oCRH
- Where
- United States
- Volunteers
- 1,387 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with…
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
- Trial name
- IMPACT-MACS (NCT07361874)
- Testing
- Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Cushing Syndrome
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
- Trial name
- NCT03708900
- Testing
- LCI699
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 12 people
- Sponsor
- RECORDATI GROUP
Cushing's Syndrome
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment.
- Trial name
- PROMPT (NCT02297945)
- Testing
- metyrapone
- Where
- 36 sites in Belgium, Germany and 6 more
- Volunteers
- 50 people
- Sponsor
- HRA Pharma